The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Global Heart Pub Date : 2025-06-16 eCollection Date: 2025-01-01 DOI:10.5334/gh.1440

Gang Fan, Hong Zuo, Lin Lin, Chao Xu, Rui Yan

{"title":"The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies.","authors":"Gang Fan, Hong Zuo, Lin Lin, Chao Xu, Rui Yan","doi":"10.5334/gh.1440","DOIUrl":null,"url":null,"abstract":"Background: Chemotherapy-induced cardiotoxicity is the leading cause of non-tumor-related mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer remain uncertain. The objective of this study was to assess the cardiovascular effects of SGLT2is in patients with cancer.Objective: We conducted a meta-analysis of cohort studies to compare the efficacy and safety of SGLT2is and placebo in patients with cancer.Results: A total of ten cohort studies, encompassing 85,185 patients, were included in this study. SGLT2is significantly decreased mortality (Risk ratios (RR) 0.52, 95% confidence interval (CI) (0.36, 0.75), I2 = 98%), heart failure (HF) (RR 0.43, 95% CI 0.24, 0.77, I2 = 75%), and arrhythmia (RR 0.33, 95% CI 0 .23, 0.49, I2 = 0%). In addition, SGLT2is decreased the incidence of adverse events. No significant difference was identified in hypoglycemia, ketoacidosis, and acute coronary syndrome (ACS).Conclusion: The present study suggest that sodium glucose cotransporter 2 inhibitors may be an efficacious and safe means for improving the prognosis of patients with cancer and diabetes. However, future large-scale randomized controlled trials are needed to further validate the results.","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"53"},"PeriodicalIF":3.1000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180433/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1440","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chemotherapy-induced cardiotoxicity is the leading cause of non-tumor-related mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer remain uncertain. The objective of this study was to assess the cardiovascular effects of SGLT2is in patients with cancer.

Objective: We conducted a meta-analysis of cohort studies to compare the efficacy and safety of SGLT2is and placebo in patients with cancer.

Results: A total of ten cohort studies, encompassing 85,185 patients, were included in this study. SGLT2is significantly decreased mortality (Risk ratios (RR) 0.52, 95% confidence interval (CI) (0.36, 0.75), I² = 98%), heart failure (HF) (RR 0.43, 95% CI 0.24, 0.77, I² = 75%), and arrhythmia (RR 0.33, 95% CI 0 .23, 0.49, I² = 0%). In addition, SGLT2is decreased the incidence of adverse events. No significant difference was identified in hypoglycemia, ketoacidosis, and acute coronary syndrome (ACS).

Conclusion: The present study suggest that sodium glucose cotransporter 2 inhibitors may be an efficacious and safe means for improving the prognosis of patients with cancer and diabetes. However, future large-scale randomized controlled trials are needed to further validate the results.

Abstract Image

查看原文本刊更多论文

葡萄糖共转运蛋白2抑制剂对抗癌患者的疗效和安全性：一项队列研究的荟萃分析

背景：化疗引起的心脏毒性是肿瘤患者非肿瘤相关死亡的主要原因。尽管葡萄糖共转运蛋白2钠抑制剂（SGLT2is）已被证明具有心血管益处，但其在癌症患者中的作用和安全性仍不确定。本研究的目的是评估SGLT2is对癌症患者心血管的影响。目的：我们进行了一项队列研究的荟萃分析，比较SGLT2is和安慰剂在癌症患者中的疗效和安全性。结果：本研究共纳入10项队列研究，共85,185例患者。sglt2i可显著降低死亡率（风险比（RR） 0.52, 95%可信区间（CI）（0.36, 0.75）， I2 = 98%）、心力衰竭（RR 0.43, 95% CI 0.24, 0.77, I2 = 75%）和心律失常（RR 0.33, 95% CI 0.23, 0.49, I2 = 0%）。此外，SGLT2is降低了不良事件的发生率。在低血糖、酮症酸中毒和急性冠状动脉综合征（ACS）方面无显著差异。结论：本研究提示葡萄糖共转运蛋白2抑制剂钠可能是改善癌症和糖尿病患者预后的有效、安全的手段。然而，需要未来的大规模随机对照试验来进一步验证结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Global Heart Medicine-Cardiology and Cardiovascular Medicine

CiteScore

5.70

自引率

5.40%

发文量

审稿时长

5 weeks

期刊介绍： Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources. Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention. Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.